- GlobeNewswire•4 hours ago
Tonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL
NEW YORK, March 28, 2017-- Tonix Pharmaceuticals Holding Corp., a company that is developing innovative pharmaceutical products to address public health challenges, announced today that it has enrolled ...
- GlobeNewswire•12 days ago
NEW YORK, March 16, 2017-- Tonix Pharmaceuticals Holding Corp., a company that is developing innovative pharmaceutical products to address public health challenges, announced today that it will effect ...
- GlobeNewswire•13 days ago
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program at Oppenheimer’s 27th Annual Healthcare Conference
TNX-102 SL, a Drug in Phase 3 Development, Recently Granted Breakthrough Therapy Designation by the FDA. Pivotal Study in Military-Related PTSD to Begin this Month. NEW YORK, March 15, 2017-- Tonix Pharmaceuticals ...
TNXP : Summary for Tonix Pharmaceuticals Holding C - Yahoo Finance
Tonix Pharmaceuticals Holding Corp. (TNXP)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||4.06 x 100|
|Ask||4.06 x 100|
|Day's Range||4.00 - 4.19|
|52 Week Range||0.33 - 4.39|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-0.19|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|